GRI BIO, Inc. Overview
Pro stress-test →GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The company focuses on modulating the activity of Natural Killer T (NKT) cells, which it describes as key regulators early in the inflammatory cascade and a functional link between the innate and adaptive immune responses.
Strategic Profile
Pro stress-test →Type I invariant NKT (iNKT) cells play a critical role in propagating injury, inflammation and fibrosis in inflammatory and fibrotic indications; GRI Bio's programs are built around inhibiting or activating specific NKT cell subsets to influence these disease processes. The company operates as a clinical-stage biotech with a proprietary NKT platform and multiple programs in development targeting high-unmet-need indications.
Competitive Landscape
Pro stress-test →Comparable biotech companies include Palisade Bio Inc (PALI), Aditxt Inc (ADTX), Aptevo Therapeutics Inc (APVO), and Xenetic Biosciences Inc (XBIO). GRI Bio differentiates through its NKT cell targeting approach, which addresses disease pathology upstream of conventional small-molecule and biologic therapies. However, the company competes in a crowded immunology space against larger, better-capitalized biotechs with established pipelines.
Industry Context
GRI BIO, Inc. operates in Clinical-stage immunology biotechnology.
Key facts
Founded: 2021 · Headquarters: La Jolla, CA · Employees: Unknown · Revenue: Pre-revenue · Market cap: $3.3M